REAL-WORLD MULTIPLE MYELOMA TREATMENT PATTERN IN MOROCCO- EVIDENCE FROM PATIENT CHART AUDIT
Author(s)
Dokuyucu O1, Gol D1, Gatta F2, Molinier S3, Sedrati M4, Serraj K5
1AMGEN, Istanbul, Turkey, 2Amgen (Europe) GmbH, Zug, Switzerland, 3A Plus A Research, Lyon, France, 4Amgen Morocco, Casablanca, Morocco, 5University hospital mohammed VI, Oujda, Morocco
OBJECTIVES: Understanding symptomatic multiple myeloma (MM) patient management, treatment patterns and outcomes in real-world practice in Morocco. METHODS: Data were collected through a cross-sectional phase (X) and retrospective (R) patient chart review (Aug/16–Oct/16) by oncologists, hematologists and internists managing >10 symptomatic MM patients during the last three months and responsible for treatment initiation. The X-phase collected treatment for MM patients seen during a 4 week time-frame, physicians’ perception on MM drugs accessibility and guidelines use. The R-phase recorded disease characteristics, including treatment response and duration. Analyses were descriptive. RESULTS: In the X-phase, a total of 237 patients were enrolled, 68% were currently undergoing treatment, of which 93% were on 1L treatment. Across all lines, thalidomide-based regimen was mainly used (72% in 1L, 60% in second-line [2L], 100% from third-line onwards [3L+]), while bortezomib-based regimen and lenalidomide-based regimen were used only in 1L (9% and 1% respectively). 95% of patients having completed a 1L were SCT eligible. In the R-Phase, a total of 200 patients were includedPhysician-assessed depth of response decreased across lines: 20% patients achieved at least a very good partial response (VGPR) in 1L, while 7% and 17% achieved at least a VGPR in 2L and 3L, respectively. Average length of therapy was 6.2 months in 1L, 5.9 and 6.2 in 2L and 3L, respectively. CONCLUSIONS: Despite the average time of treatment duration, low response rates from 1L onwards suggest a need for more effective therapies in Morocco to support patients in achieving better and sustained responses across all lines.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN336
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior
Disease
Oncology